TORONTO–(BUSINESS WIRE)–Verkazia Reimbursement for New Brunswick
Author: Business Wire
Verkazia™ (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is now Publicly Reimbursed in New Brunswick
TORONTO–(BUSINESS WIRE)–Verkazia Reimbursement for New Brunswick
Deep 6 AI Announces Substantial Expansion of its Innovative AI-Based Clinical Trial Acceleration Software and Research Ecosystem
PASADENA, Calif.–(BUSINESS WIRE)–Deep 6 AI, the leader in artificial intelligence (AI)-based clinical trial acceleration software (CTAS), today announced significant growth.
Aurion Biotech Names Edward Holland, MD, Chief Medical Advisor
SEATTLE & BOSTON & TOKYO–(BUSINESS WIRE)–Aurion Biotech has appointed Edward Holland, MD, as Chief Medical Advisor.
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, entered…
Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
Enspryng (Satralizumab) von Chugai, von der Europäischen Kommission als erste subkutane Behandlung für zu Hause bei Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) zugelassen
TOKIO, Japan–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab heute bekannt, dass Roche von der Europäischen Kommission die Marktzulassung für den pH-abhängig bindenden humanisierten monoklonalen Anti-IL-6-Rezeptor-Antikörper Enspryn…
歐盟委員會核准中外製藥的Enspryng (Satralizumab)作為首款用於治療泛視神經脊髓炎(NMOSD)的居家皮下治療藥物
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO:4519)今天宣布,歐盟委員會已向羅氏(Roche)簽發市售授權,核准中外製藥研製的pH依賴型結合人源化抗IL-6受體單株抗體Enspryng® (satralizumab),將其作為抗水通道蛋白-4抗體(AQP4-IgG)血清陽性的成人及12歲以上青少年泛視神經脊髓炎(NMOSD)患者的首個皮下治療選擇,作為單藥治療或聯合免疫抑制治療(IST…
Riassunto: Teva e Bioeq annunciano una collaborazione commerciale per i farmaci biosimilari
TEL AVIV, Israele e ZURIGO–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE: e TASE: TEVA) e Bioeq AG (“Bioeq”) oggi hanno annunciato di avere stretto una collaborazione strategica per la commercializzazione esclusiva di FYB201 prodotto da B…
Teva und Bioeq geben Vertriebspartnerschaft für Biosimilar bekannt
TEL AVIV, Israel, und ZÜRICH, Schweiz–(BUSINESS WIRE)–Wie Teva Pharmaceutical Industries Ltd. (NYSE: und TASE: TEVA) und die Bioeq AG („Bioeq“) heute bekannt gaben, sind die beiden Unternehmen eine strategische Partnerschaft für die exklusive Vermark…
Alcon Announces Executive Committee Changes
GENEVA–(BUSINESS WIRE)–Alcon Announces Executive Committee Changes
Alcon Announces Executive Committee Changes
GENEVA–(BUSINESS WIRE)–Alcon Announces Executive Committee Changes
Samenvatting: Teva en Bioeq kondigen commerciële samenwerking aan voor Biosimilar
TEL AVIV, Israël & ZURRICH–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE: en TASE: TEVA) en Bioeq AG (“Bioeq”) hebben vandaag aangekondigd dat ze een strategisch partnerschap zijn aangegaan voor de exclusieve commercialisering van Bioeq’s…
Resumen: Teva y Bioeq anuncian una asociación comercial para un biosimilar
TEL AVIV, Israel y ZURICH–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE: y TASE: TEVA) y Bioeq AG (“Bioeq”) han anunciado hoy que han firmado una asociación estratégica para la comercialización exclusiva de FYB201 de Bioeq, un candidato a…
Teva et Bioeq annoncent un partenariat commercial dans le domaine des biosimilaires
TEL AVIV, Israël, et ZURICH–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA) et Bioeq AG (“Bioeq”) ont annoncé aujourd’hui avoir conclu un partenariat stratégique pour la commercialisation exclusive du FYB201 de Bioeq, un can…
Riassunto: Enspryng (Satralizumab) di Chugai approvato dalla Commissione europea quale primo trattamento sottocutaneo a domicilio per il disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha annunciato oggi che a Roche è stata concessa l’Autorizzazione all’immissione in commercio della Commissione europea per l’anticorpo monoclonale umanizzato anti-recettore IL-6 lega…
Pas de répit pour les yeux fatigués : Une pandémie d'utilisation accrue de la vision de près chez les enfants canadiens(1) – Sondage CooperVision
TORONTO–(BUSINESS WIRE)–Alors que la perspective du retour à la normale semble moins lointaine, un nouveau sondage réalisé par CooperVision Canada et par Maru/Blue1 suggère que la pandémie pourrait avoir généré des habitudes de vision de près, ce qui…
No Rest for the Weary Eyes: A Pandemic of Increased Near-Vision Use for Canadian Children(1) – CooperVision Survey
TORONTO–(BUSINESS WIRE)–While the horizon of a return to normal seems less distant, a new survey by CooperVision Canada and Maru/Blue1 suggests that the pandemic may have generated near-vision habits, which according to experts could have an impact o…
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
DUBLIN–(BUSINESS WIRE)–Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Teva and Bioeq Announce Commercial Partnership for Biosimilar
TEL AVIV, Israel & ZURICH–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG (“Bioeq”) today announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq’s FYB201, a b…